Literature DB >> 8076989

Age-related prevalence of Helicobacter pylori antibodies in Indian subjects.

H H Gill1, P Majmudar, K Shankaran, H G Desai.   

Abstract

OBJECTIVE: To determine the age-related prevalence of Helicobacter pylori antibodies in Indian subjects without upper gastrointestinal symptoms.
MATERIAL AND METHODS: Sera of 340 subjects without any upper gastrointestinal complaints were screened for IgG and IgA Helicobacter pylori antibodies by the ELISA technique.
RESULTS: The prevalence of IgG and IgA antibodies was 22%, 56% and 87% and 48%, 58% and 83% in 0-4, 5-9 and 10-19 year age groups respectively; thereafter it remained almost constant upto fifth decade. A significant fall in IgG and IgA prevalence was observed from fifth to seventh decades.
CONCLUSION: Our data indicate that in India exposure to Helicobacter pylori occurs early in life and is widespread; about 83% of the population is exposed to Helicobacter pylori during the first two decades of life. The comparable prevalence rates of IgG antibodies to Helicobacter pylori and hepatitis A virus, in different age groups, in India and in the West, suggest a feco-oral mode of transmission for Helicobacter pylori.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8076989

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  10 in total

Review 1.  Presentation and management of Helicobacter pylori infection in childhood.

Authors:  U Blecker; N K Mittal; D I Mehta
Journal:  Indian J Pediatr       Date:  1996 May-Jun       Impact factor: 1.967

2.  Study of transmission routes of Helicobacter pylori in relation to seroprevalence of hepatitis A virus.

Authors:  T Furuta; T Kamata; M Takashima; H Futami; H Arai; H Hanai; E Kaneko
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

3.  Association of Helicobacter pylori infection and giardiasis: results from a study of surrogate markers for fecal exposure among children.

Authors:  Edson Duarte Moreira; Victor Bastos Nassri; Rafaela Sousa Santos; Junisia Ferraz Matos; Wilson Andrade de Carvalho; Celia Stolve Silvani; Ciria Santana e Sant'ana
Journal:  World J Gastroenterol       Date:  2005-05-14       Impact factor: 5.742

4.  A localized case-control study of extra-gastric manifestations of Helicobacter pylori infection in children.

Authors:  Rasha Abdel-Raouf Afifi; Dina Kamal Ali; Iman Abdel-Mohsen Shaheen
Journal:  Indian J Pediatr       Date:  2010-12-17       Impact factor: 1.967

Review 5.  Upper gastrointestinal bleeding: etiology and management.

Authors:  N K Arora; S Ganguly; P Mathur; A Ahuja; A Patwari
Journal:  Indian J Pediatr       Date:  2002-02       Impact factor: 1.967

6.  Frequency of Helicobacter pylori and CagA antibody in patients with gastric neoplasms and controls: the Indian enigma.

Authors:  Uday C Ghoshal; Shridhar Tiwari; Sadhna Dhingra; Rakesh Pandey; Ujjala Ghoshal; Shweta Tripathi; Himani Singh; V K Gupta; A K Nagpal; Sita Naik; Archana Ayyagari
Journal:  Dig Dis Sci       Date:  2008-03-20       Impact factor: 3.199

Review 7.  Causal role of Helicobacter pylori infection in gastric cancer: an Asian enigma.

Authors:  Kartar Singh; Uday C Ghoshal
Journal:  World J Gastroenterol       Date:  2006-03-07       Impact factor: 5.742

8.  Prevalence of Helicobacter pylori, cytomegalovirus, and Chlamydia pneumoniae immunoglobulin seropositivity in coronary artery disease patients and normal individuals in North Indian population.

Authors:  Rohit Tewari; Vs Nijhawan; Mn Mishra; Puja Dudeja; Tk Salopal
Journal:  Med J Armed Forces India       Date:  2012-01-18

Review 9.  Epidemiology and pathophysiology of Helicobacter pylori infection in children.

Authors:  Jagadish C Das; Nibedita Paul
Journal:  Indian J Pediatr       Date:  2007-03       Impact factor: 5.319

10.  Prevalence of Helicobacter pylori in children and their family members in a district in Turkey.

Authors:  Abdullah Ceylan; Ercan Kirimi; Oğuz Tuncer; Kürşat Türkdoğan; Sevil Ariyuca; Nesrin Ceylan
Journal:  J Health Popul Nutr       Date:  2007-12       Impact factor: 2.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.